Forte Biosciences
FBRX
34 hedge funds and large institutions have $3.8M invested in Forte Biosciences in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 3 closing their positions.
2,675% more call options, than puts
Call options by funds: $111K | Put options by funds: $4K
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
33% more capital invested
Capital invested by funds: $2.85M → $3.8M (+$949K)
3% more funds holding
Funds holding: 33 → 34 (+1)
0.2% more ownership
Funds ownership: 0.53% → 0.72% (+0.2%)
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$50K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$13.8K |
| 3 |
FIA
FNY Investment Advisers
New York
|
+$7.69K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$4.69K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$171K |
| 2 |
Two Sigma Advisers
New York
|
-$87.7K |
| 3 |
Millennium Management
New York
|
-$65.1K |
| 4 |
Two Sigma Investments
New York
|
-$35K |
| 5 |
E
Ergoteles
New York
|
-$19K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Russell Investments Group
London,
United Kingdom
| $453 | – | – | – |
|
|
LWCFA
27
Loring Wolcott & Coolidge Fiduciary Advisors
Boston,
Massachusetts
| $193 | – | – | – |
|
28
Bank of America
Charlotte,
North Carolina
| $163 | -$77 | -3 | -30% |
|
29
Wells Fargo
San Francisco,
California
| $126 | +$26 | +1 | +25% |
|
|
TWC
30
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $104 | – | – | – |
|
|
LFG
31
Larson Financial Group
St Louis,
Missouri
| $35 | – | – | – |
|
|
E
32
Ergoteles
New York
| – | -$19K | -728 | Closed |
|
|
VF
33
Virtu Financial
New York
| – | -$15K | -566 | Closed |
|
34
Man Group
London,
United Kingdom
| – | -$12K | -430 | Closed |
|
35
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$51 | -2 | -22% |
|
FBRX Hedge Fund Activity: Q4 2022 in Review
34 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q4 2022, worth a combined $3.8M — up 33% from $2.85M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new FBRX positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 12 trimmed.
The largest buyer was Newtyn Management, adding an estimated $50K. The largest seller was Renaissance Technologies, cutting an estimated $171K.
- 34 institutional investors held Forte Biosciences (FBRX) as of Q4 2022, up from 33 in Q3 2022.
- Funds reported $3.8M of Forte Biosciences stock for Q4 2022, up 33% quarter-over-quarter.
- 4 funds opened new Forte Biosciences positions in Q4 2022 and 3 closed out, a net change of +1 holder.
- The largest Forte Biosciences buyer in Q4 2022 was Newtyn Management, an estimated $50K added.
- The largest Forte Biosciences seller in Q4 2022 was Renaissance Technologies, an estimated $171K sold.
Based on aggregated 13F filings for Q4 2022.